Opioid toxicity due to CNS depressant polypharmacy: A case report.

The Mental Health Clinician Pub Date : 2021-03-31 eCollection Date: 2021-03-01 DOI:10.9740/mhc.2021.03.070
Christine Lee, Annabelle Wanson, Sarah Frangou, David Chong, Katelyn Halpape
{"title":"Opioid toxicity due to CNS depressant polypharmacy: A case report.","authors":"Christine Lee,&nbsp;Annabelle Wanson,&nbsp;Sarah Frangou,&nbsp;David Chong,&nbsp;Katelyn Halpape","doi":"10.9740/mhc.2021.03.070","DOIUrl":null,"url":null,"abstract":"<p><p>The interaction between methadone and central nervous system depressants can cause serious adverse effects, including profound sedation, respiratory depression, coma, and death. This poses a challenge in the treatment of patients with concurrent psychiatric and substance use disorders as the combined use is often unavoidable. We report a case of a patient with opioid use disorder, mood disorder unspecified, chronic pain, and chronic obstructive pulmonary disease who experienced 2 serious episodes of CNS and respiratory depression due to polypharmacy-induced opioid toxicity. Careful consideration of pharmacokinetics, pharmacodynamics, and patient-specific factors was imperative to identify the suspected contributing medications: methadone, lorazepam, divalproex, gabapentin, and cyclobenzaprine. Cognitive and system factors that contributed to these adverse events and strategies to mitigate risk of recurrence were also identified.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"11 2","pages":"70-74"},"PeriodicalIF":0.0000,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/cc/i2168-9709-11-2-70.PMC8019539.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Mental Health Clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/mhc.2021.03.070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

The interaction between methadone and central nervous system depressants can cause serious adverse effects, including profound sedation, respiratory depression, coma, and death. This poses a challenge in the treatment of patients with concurrent psychiatric and substance use disorders as the combined use is often unavoidable. We report a case of a patient with opioid use disorder, mood disorder unspecified, chronic pain, and chronic obstructive pulmonary disease who experienced 2 serious episodes of CNS and respiratory depression due to polypharmacy-induced opioid toxicity. Careful consideration of pharmacokinetics, pharmacodynamics, and patient-specific factors was imperative to identify the suspected contributing medications: methadone, lorazepam, divalproex, gabapentin, and cyclobenzaprine. Cognitive and system factors that contributed to these adverse events and strategies to mitigate risk of recurrence were also identified.

Abstract Image

多药性中枢神经系统抑制剂引起的阿片毒性:1例报告。
美沙酮与中枢神经系统抑制剂相互作用可引起严重的不良反应,包括深度镇静、呼吸抑制、昏迷和死亡。这对同时患有精神和物质使用障碍的患者的治疗提出了挑战,因为联合使用通常是不可避免的。我们报告了一例阿片类药物使用障碍,未指明的情绪障碍,慢性疼痛和慢性阻塞性肺疾病患者,由于多药性阿片类药物毒性,经历了2次严重的中枢神经系统和呼吸抑制发作。仔细考虑药代动力学、药效学和患者特异性因素是确定可疑药物的必要条件:美沙酮、劳拉西泮、双丙戊酸、加巴喷丁和环苯扎林。导致这些不良事件的认知和系统因素以及减轻复发风险的策略也被确定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信